Molecular Profile | NPM1-ALK ALK L1196M ALK D1203N |
Therapy | Ceritinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | decreased response |
Create By | c-seddy |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | NPM1-ALK ALK L1196M ALK D1203N | Advanced Solid Tumor | decreased response | Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750). | 25421750 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(25421750) | Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. | Full reference... |